54 results about "Proton pump" patented technology

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

A heterobicyclic derivative represented by chemical formula (I), according to the present invention, has a reversible proton pump inhibitory effect, and thus the heterobicyclic derivative and a pharmaceutical composition comprising same can be effectively used as a therapeutic agent for diseases associated with gastric acid secretion, particularly, as P-CAB.

The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

The invention provides a primer combination for detecting helicobacter pylori and application of the primer combination. The primer combination is used for strain identification of the helicobacter pylori and detection of gastric cancer risk sites, antibiotic resistance sites, virulence genotyping and human proton pump inhibitor drug metabolism. On the basis of multiple PCR and targeted high-throughput sequencing technologies, specific targeted amplification primers are designed and mixed, so that the helicobacter pylori identification can be completed, gastric cancer risk sites, antibiotic resistance genes, virulence typing and human proton pump inhibitor drug metabolism genes of the helicobacter pylori can be detected, and finally, the helicobacter pylori can be detected. A quantitative algorithm of approximate concentration of helicobacter pylori is also introduced into the system, so that more sensitive, accurate and comprehensive detection of helicobacter pylori is realized.

The invention belongs to the technical field of proton pump inhibition medicine preparations, and relates to a rabeprazole sodium enteric-coated tablet and a preparation method thereof. The technical problems that an existing rabeprazole sodium enteric-coated tablet is insufficient in stability, lagged in dissolution and the like are solved. The enteric-coated tablet consists of a tablet core and an enteric-coated coating layer wrapped outside the tablet core, wherein the tablet core comprises auxiliary materials such as rabeprazole sodium, a filling agent, an adhesive, a stable dissolution promoter and the like; the enteric coating layer comprises an enteric coating material, a plasticizer, an anti-sticking agent and a solvent. Through the synergistic effect of the compound stabilizer and process control, the stability and dissolution performance of the enteric-coated tablet are synergistically improved, meanwhile, the production process is simplified, and the preparation method is suitable for industrial application.

The invention relates to the technical field of biological engineering, and discloses a method for enhancing the urea circulation function of a 3D biological printing liver organ, which comprises the following steps: a cell preparation step: through a genetic engineering technology, enabling mitochondria of liver cells to express a light-driven proton pump, and enabling intracellular expression of a fluorescent probe for reporting ammonia concentration; an organ construction step: mixing the cells with hydrogel to prepare bio-ink, and constructing a three-dimensional liver organ by using a 3D biological printing technology; a system integration step: placing the liver organ in an integrated photoelectric regulation and control system capable of monitoring a fluorescence signal in real time and applying illumination; and a closed-loop enhancement step: the system monitors the ammonia concentration in real time, and when the ammonia concentration exceeds a preset threshold value, illumination is automatically applied to activate the proton pump, so that the urea circulation function is enhanced as required. Through closed-loop light control and a subcellular organelle energy channel, on-demand, efficient and high-temporal-spatial-resolution dynamic enhancement of the liver organ urea circulation function is achieved.

The present invention relates to a novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a pharmaceutical composition for potassium-competitive inhibition of gastric acid secretion and a pharmaceutical composition for preventing or treating diseases caused by gastric acid secretion disorder, the pharmaceutical composition containing the novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof as an active component. The pyrrole derivative compound or the like according to the present invention is a potassium-competitive acid blocker (PCAB) and has an excellent H+ / K+ adenosine triphosphatase (ATPase) (proton pump) inhibition effect, and is thus widely used as a therapeutic agent for diseases caused by gastric acid secretion disorder.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

A pharmaceutical formulation according to some embodiments comprises: an immediate-release part for eluting an active ingredient in a pH-independent manner; and an enteric part for eluting the active ingredient in a pH-dependent manner, wherein the active ingredient may comprise a proton pump inhibitor, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Some embodiments of the present invention enable immediate absorption of drugs while maintaining prolonged pharmacological efficacy.

Helicobacter pylori (HP) is a chronic bacterium that infects the gastric mucosa. It is widespread in the general population, with an infection rate between 55% and 70%. HP is closely related to gastric ulcers and gastritis. Western medicine treatment for HP infection is relatively complex, including bismuth substituents and proton pump inhibitors plus two antibiotics. Gastric ulcers and gastritis are common digestive system diseases. Compound 1, "Exterminate the Ghost," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Scutellaria baicalensis and Fraxinus chinensis, which can eradicate HP. Compound 2, "Ulcer Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Rheum palmatum and Bletilla striata, which can cure gastric ulcers. Compound 3, "Gasitis Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Glycyrrhiza uralensis or Taraxacum mongolicum, made into a tea bag, which can cure chronic gastritis.

A tricyclic derivative represented by chemical formula (I), of the present invention, has a reversible proton pump inhibitory effect, and thus the tricyclic derivative and a pharmaceutical composition comprising same can be effectively used as a therapeutic agent for diseases associated with gastric acid secretion, particularly, as P-CAB.

The present invention relates to a pharmaceutical composition a first comprising: unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical composition according to the present invention is divided into the first unit and the second unit, thus preventing direct contact between the drugs. Therefore, stability is achieved and the effect on the individual release of the respective drugs is minimized, and thus improved elution is exhibited.

A fusion protein comprises (1) a first moiety that targets and orients the fusion protein to mitochondria inner membrane and (2) a second moiety that provides light-activated proton pump function when integrate into the mitochondria inner membrane. The fusion protein can be used for modulating hypoxia signaling in a subject, revitalizing cells, modulating T cell function, improving feed efficiency, prolonging lifespan and treating cancer.

This invention provides a method for preparing a proton pump inhibitor thioether intermediate. The method involves reacting 3,5-dimethyl-4-methoxy-2-pyridinemethanethiol as a raw material with paraformaldehyde to obtain an intermediate, which is then further reacted with 4-methoxy-o-phenylenediamine, followed by post-treatment to obtain omeprazole thioether. This preparation method is novel, simple to operate, produces a high-purity product, and is suitable for industrial production.

An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

To provide a pediatric suspension formulation.SOLUTION: The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.SELECTED DRAWING: None

A fusion protein comprises (1) a first moiety that targets and orients the fusion protein to mitochondria inner membrane and (2) a second moiety that provides light-activated proton pump function when integrated into the mitochondria inner membrane. The fusion protein can be used for modulating hypoxia signaling in a subject, treating neurodegenerative diseases, protecting against stress, ameliorating symptoms of metabolic disorders and treating cancer.

A tricyclic derivative represented by chemical formula (I), of the present invention, has a reversible proton pump inhibitory effect, and thus the tricyclic derivative and a pharmaceutical composition comprising same can be effectively used as a therapeutic agent for diseases associated with gastric acid secretion, particularly, as P-CAB.

The present application relates to a kind of amoxicillin gastric retention sustained-release preparation, which contains amoxicillin, sustained-release material, swelling agent and other pharmaceutical adjuvant, preferably also contains stabilizer or ion regulator.The combination of the above-mentioned adjuvant can be retained in the stomach for up to 24 hours, the complete release time is 10-24h, which can significantly prolong the retention time of amoxicillin in the stomach, has the advantages of fast floating, high effective concentration of drug in the stomach, long stable concentration time, and is beneficial to reduce the frequency of drug administration of patients;Further preferably, it is made into a double-layer tablet containing immediate-release layer, which can quickly reach effective concentration and also can be released slowly and continuously, maintaining effective concentration for a long time;When combined with proton pump inhibitors such as vonolabian, etc., combination kit or compound, only 1-2 times per day is needed, which can further improve the therapeutic effect and patient compliance.

A proton pump modulator, and a use of the proton pump modulator in preparing a reagent. The reagent is used for improving learning ability, treating cognitive impairment, and / or treating neurodegenerative diseases. Also involved are an ATP6V1B2 modulator and a use thereof in preparing a reagent used for improving learning ability, treating cognitive impairment, and / or treating neurodegenerative diseases.

This invention provides a lyophilized powder injection of a proton pump inhibitor and its use therein, the lyophilized powder injection comprising a compound of formula (I) and an excipient. The powder injection provided by this invention is stable in properties, has controllable quality, and its preparation process is highly reproducible, meeting the needs of commercial production. Formula (I).

The present application relates to use of a proton pump regulator in the preparation of a reagent. The proton pump regulator can regulate ATP6V1B2 and / or a functional active fragment thereof. The reagent can be used for preventing and / or treating diseases, including sleep disorders.

The present invention relates to: a novel 4-cyclopropyl pyrrole derivative exhibiting proton pump inhibitory activity and, more specifically, to a 4-cyclopropyl pyrrole derivative exhibiting excellent proton pump inhibitory activity or a pharmaceutically acceptable salt thereof; and a use thereof for preventing or treating gastrointestinal inflammatory diseases or gastric acid-related diseases.

This invention provides a bioimaging device based on photosensitive proteins, comprising a photosensitive imaging unit, an image reading unit, and an image reconstruction unit. The photosensitive imaging unit includes a photosensitive protein membrane and two pixel grid gel layers. The photosensitive protein membrane includes a photosensitive protein with a light-driven proton pump function. The photosensitive imaging unit converts the light intensity information of an external target image into proton concentration information of the gel material within each grid of the pixel grid gel layers. The image reading unit detects the proton concentration change information of the gel material within each grid of the pixel grid gel layers. The image reconstruction unit restores the proton concentration change information of the gel material to the light intensity information at each grid, and converts the light intensity information at the grid into grayscale information to obtain the target image. The bioimaging device provided by this invention has high image resolution.

Compositions comprising (i) a cross-linked polymeric chelator comprising a plurality of cross-linked polyamine polymer backbone chains and one or more chelators covalently coupled thereto, and (ii) an agent selected from an antacid, a histamine H2-receptor antagonist, a proton pump inhibitor, and a combination thereof. Also disclosed are methods of using a composition comprising the cross-linked polymeric chelator in combination with the agent, e.g., for removing metal from a medium or treating iron overload disease.

The invention relates to application of a proton pump regulating agent for regulating ATP6V1B2 and / or a functional active fragment thereof in preparation of a reagent for preventing and / or treating diseases, and the diseases comprise cerebral apoplexy.

Omeprazole is used as a widely applied proton pump inhibitor and is mainly used for treating various diseases caused by hyperacidity, such as gastric ulcer, duodenal ulcer, reflux esophagitis and the like. The invention relates to a novel application of a commercially available medicine omeprazole, namely the omeprazole has remarkable anti-aging activity. The research on model organism caenorhabditis elegans finds that omeprazole can significantly prolong the life of nematodes. Specifically, when the nematodes are cultured in culture media containing 1.6 mg / mL omeprazole and 3.2 mg / mL omeprazole, the service lives of the nematodes are prolonged by 47.80% and 61.51% respectively, and the effect is extremely rare in current drug research.

The invention relates to the technical field of prescription auditing, and discloses an intelligent pharmacy platform based on linkage of a hospital information system and a reasonable medication system, which screens and manages key controlled medicines such as traditional Chinese medicine decoction pieces, proton pump inhibitors, analgesics, enteral and parenteral nutrition preparations and the like through a clinical pharmacist informatization integrated management system. Through an intelligent management platform, precise control and intervention of traditional Chinese medicine decoction pieces and key monitoring drugs such as proton pump inhibitors, analgesics and enteral and parenteral nutrition preparations in medical institutions are realized, and a standardized medication path is established. The method successfully solves the core problems that the traditional Chinese medicine decoction piece auditing rule is single and does not accord with the reality in the prescription auditing process in the prior art, the medicine is emphatically monitored, and the medicine diameter management of proton pump inhibitor enteral and parenteral nutrition, analgesics and enteral and parenteral nutrition preparations is not in place. A comprehensive and practical solution is provided for optimization of a prescription auditing system and formulation of clinical drug paths.

Omeprazole, as a widely used proton pump inhibitor, is mainly used for the treatment of various diseases caused by excessive gastric acid, such as gastric ulcer, duodenal ulcer and reflux esophagitis. The present application relates to a new use of a commercially available drug omeprazole, i.e. it has significant anti-aging activity. The present application found that omeprazole can significantly prolong the life of nematodes through research using model organisms Caenorhabditis elegans. Specifically, when the nematodes are cultured in a medium containing 1.6 mg / mL and 3.2 mg / mL omeprazole, their life is prolonged by 47.80% and 61.51% respectively, which is extremely rare in current drug research.